Aspirin: Where we are now and where we are going
Join us in Paris during ESC 2019 for an intimate meeting with members of the International Aspirin Foundation’s Scientific Advisory Board, on Monday 2nd September at the Balzac – The Hub from 4.00-4.30pm.
Professors Peter Rothwell (University of Oxford); Lina Badimon (Cardiovascular Research Centre Barcelona) and Michael Gaziano (Harvard University) will highlight the role of The Foundation and its engagement with the scientific community, providing a critical forum for many leading aspirin researchers worldwide to share their views and debate trial data. This is achieved through science awards; symposia and conferences. Find out more about entry criteria and applying for our £20,000 Senior Science Award.
Professor Michael Gaziano, Harvard Medical School, will use clinical cases to bring into context the evidence for aspirin as a disease prevention agent.
Professor Gaziano will draw on the past evidence base for aspirin in both CVD and cancer and add this to recent and future clinical trial work. He will then guide the audience through the skill of accurately assessing the right level of CVD / cancer risk combined with the ability to accurately predict and potentially manage bleeding side effects in order to make good decisions around who is most likely to reap the rewards of aspirin disease prevention.